Anti-acrolein treatment improves behavioral outcome and alleviates myelin damage in experimental autoimmune enchephalomyelitis mouse

Neuroscience

Volumn 173, Issue , 2011, Pages 150-155

  Leung, G ^a   Sun, W ^a   Zheng, L ^a,b   Brookes, S ^a   Tully, M ^b,c   Shi, R ^a,b  

^a PURDUE UNIVERSITY   (United States)

^b PURDUE UNIVERSITY   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Acrolein; Demyelination; EAE; Hydralazine; Multiple sclerosis

Indexed keywords

ACROLEIN; HYDRALAZINE;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DEMYELINATION; DRUG ACTIVITY; DRUG EFFICACY; FEMALE; HYPOTENSION; LIPID PEROXIDATION; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN INTERACTION; SPINAL CORD; SYMPTOM;

ACROLEIN; ANIMALS; ANTIOXIDANTS; BEHAVIOR, ANIMAL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HYDRALAZINE; IMMUNOBLOTTING; MICE; MICE, INBRED C57BL; MYELIN SHEATH; SPINAL CORD;

EID: 78650678757     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2010.11.018     Document Type: Article

References (40)

1. Adams J.D., Klaidman L.K. Acrolein-induced oxygen radical formation. Free Radic Biol Med 1993, 15:187-193.
2. Burcham P.C., Fontaine F.R., Kaminskas L.M., Petersen D.R., Pyke S.M. Protein adduct-trapping by hydrazinophthalazine drugs: mechanisms of cytoprotection against acrolein-mediated toxicity. Mol Pharmacol 2004, 65:655-664.
3. Burcham P.C., Kaminskas L.M., Fontaine F.R., Petersen D.R., Pyke S.M. Aldehyde-sequestering drugs: tools for studying protein damage by lipid peroxidation products. Toxicology 2002, 181-182:229-236.
4. Burcham P.C., Kerr P.G., Fontaine F. The antihypertensive hydralazine is an efficient scavenger of acrolein. Redox Rep 2000, 5:47-49.
5. Burcham P.C., Pyke S.M. Hydralazine inhibits rapid acrolein-induced protein oligomerization: role of aldehyde scavenging and adduct trapping in cross-link blocking and cytoprotection. Mol Pharmacol 2006, 69:1056-1065.
6. Compston A., Coles A. Multiple sclerosis. Lancet 2008, 372:1502-1517.
7. Esterbauer H., Schaur R.J., Zollner H. Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic Biol Med 1991, 11:81-128.
8. Ghilarducci D.P., Tjeerdema R.S. Fate and effects of acrolein. Rev Environ Contam Toxicol 1995, 144:95-146.
9. Gilgun-Sherki Y., Melamed E., Offen D. The role of oxidative stress in the pathogenesis of multiple sclerosis: the need for effective antioxidant therapy. J Neurol 2004, 251:261-268.
10. Gold R., Linington C., Lassmann H. Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research. Brain 2006, 129:1953-1971.
11. Halliwell B., Gutteridge J.M.C. Free radicals in biology and medicine 1999, Oxford University Press, Oxford.
12. Hamann K., Nehrt G., Ouyang H., Duerstock B., Shi R. Hydralazine inhibits compression and acrolein-mediated injuries in ex vivo spinal cord. J Neurochem 2008, 104:708-718.
13. Hamann K., Durkes A., Ouyang H., Uchida K., Pond A., Shi R. Critical role of acrolein in secondary injury following ex vivo spinal cord trauma. J Neurochem 2008, 107:712-721.
14. Hamann K., Shi R. Acrolein scavenging: a potential novel mechanism of attenuating oxidative stress following spinal cord injury. J Neurochem 2009, 111:1348-1356.
15. Kalyvas A., David S. Cytosolic phospholipase A2 plays a key role in the pathogenesis of multiple sclerosis-like disease. Neuron 2004, 41:323-335.
16. Kaminskas L.M., Pyke S.M., Burcham P.C. Reactivity of hydrazinophthalazine drugs with the lipid peroxidation products acrolein and crotonaldehyde. Org Biomol Chem 2004, 2:2578-2584.
17. Kaminskas L.M., Pyke S.M., Burcham P.C. Strong protein adduct trapping accompanies abolition of acrolein-mediated hepatotoxicity by hydralazine in mice. J Pharmacol Exp Ther 2004, 310:1003-1010.
18. Kehrer J.P., Biswal S.S. The molecular effects of acrolein. Toxicol Sci 2000, 57:6-15.
19. Liu-Snyder P., McNally H., Shi R., Borgens R.B. Acrolein-mediated mechanisms of neuronal death. J Neurosci Res 2006, 84:209-218.
20. Lovell M.A., Xie C., Markesbery W.R. Acrolein is increased in Alzheimer's disease brain and is toxic to primary hippocampal cultures. Neurobiol Aging 2001, 22:187-194.
21. Luo J., Shi R. Acrolein induces axolemmal disruption, oxidative stress, and mitochondrial impairment in spinal cord tissue. Neurochem Int 2004, 44:475-486.
22. Luo J., Shi R. Acrolein induces oxidative stress in brain mitochondria. Neurochem Int 2005, 46:243-252.
23. Luo J., Uchida K., Shi R. Accumulation of acrolein-protein adducts after traumatic spinal cord injury. Neurochem Res 2005, 30:291-295.
24. Luo J., Robinson J.P., Shi R. Acrolein-induced cell death in PC12 cells: role of mitochondria-mediated oxidative stress. Neurochem Int 2005, 47:449-457.
25. Montine T.J., Neely M.D., Quinn J.F., Beal M.F., Markesbery W.R., Roberts L.J., Morrow J.D. Lipid peroxidation in aging brain and Alzheimer's disease. Free Radic Biol Med 2002, 33:620-626.
26. Morell P., Quarles R.H. Basic neurochemistry: molecular, cellular, and medical aspects 1999, Lippincott Williams & Wilkins, Philadelphia, PA. G.J. Siegel, B.W. Agranoff, R.W. Alberts, P.B. Molinoff (Eds.).
27. Shao B., O'Brien K.D., McDonald T.O., Fu X., Oram J.F., Uchida K., Heinecke J.W. Acrolein modifies apolipoprotein A-I in the human artery wall. Ann N Y Acad Sci 2005, 1043:396-403.
28. Shao B., Fu X., McDonald T.O., Green P.S., Uchida K., O'Brien K.D., Oram J.F., Heinecke J.W. Acrolein impairs ATP binding cassette transporter A1-dependent cholesterol export from cells through site-specific modification of apolipoprotein A-I. J Biol Chem 2005, 280:36386-36396.
29. Shao C., Roberts K.N., Markesbery W.R., Scheff S.W., Lovell M.A. Oxidative stress in head trauma in aging. Free Radic Biol Med 2006, 41:77-85.
30. Shi R., Luo J., Peasley M.A. Acrolein inflicts axonal membrane disruption and conduction loss in isolated guinea pig spinal cord. Neuroscience 2002, 115:337-340.
31. Shibata N., Nagai R., Miyata S., Jono T., Horiuchi S., Hirano A., Kato S., Sasaki S., Asayama K., Kobayashi M. Nonoxidative protein glycation is implicated in familial amyotrophic lateral sclerosis with superoxide dismutase-1 mutation. Acta Neuropathol (Berl) 2000, 100:275-284.
32. Shields D.C., Banik N.L. Pathophysiological role of calpain in experimental demyelination. J Neurosci Res 1999, 55:533-541.
33. Shields D.C., Schaecher K.E., Saido T.C., Banik N.L. A putative mechanism of demyelination in multiple sclerosis by a proteolytic enzyme, calpain. Proc Natl Acad Sci U S A 1999, 96:11486-11491.
34. Smith K.J., Kapoor R., Felts P.A. Demyelination: the role of reactive oxygen and nitrogen species. Brain Pathol 1999, 9:69-92.
35. Trapp B.D., Nave K.A. Multiple sclerosis: an immune or neurodegenerative disorder?. Annu Rev Neurosci 2008, 31:247-269.
36. Trapp B.D., Peterson J., Ransohoff R.M., Rudick R., Mork S., Bo L. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998, 338:278-285.
37. Trapp B.D., Ransohoff R., Rudick R. Axonal pathology in multiple sclerosis: relationship to neurologic disability. Curr Opin Neurol 1999, 12:295-302.
38. Uchida K., Kanematsu M., Morimitsu Y., Osawa T., Noguchi N., Niki E. Acrolein is a product of lipid peroxidation reaction. Formation of free acrolein and its conjugate with lysine residues in oxidized low density lipoproteins. J Biol Chem 1998, 273:16058-16066.
39. Uchida K., Kanematsu M., Sakai K., Matsuda T., Hattori N., Mizuno Y., Suzuki D., Miyata T., Noguchi N., Niki E., Osawa T. Protein-bound acrolein: potential markers for oxidative stress. Proc Natl Acad Sci U S A 1998, 95:4882-4887.
40. Wood P.L., Khan M.A., Moskal J.R., Todd K.G., Tanay V.A., Baker G. Aldehyde load in ischemia-reperfusion brain injury: neuroprotection by neutralization of reactive aldehydes with phenelzine. Brain Res 2006, 1122:184-190.